{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T21:40:39Z","timestamp":1790199639277,"version":"4.1.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2025,3]]},"DOI":"10.1016\/j.critrevonc.2025.104623","type":"journal-article","created":{"date-parts":[[2025,1,18]],"date-time":"2025-01-18T03:06:46Z","timestamp":1737169606000},"page":"104623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["\u00ab Augmented radiotherapy \u00bb in the management of high-risk prostate cancer (PCa): A systematic review"],"prefix":"10.1016","volume":"207","author":[{"given":"Jennifer","family":"Le Gu\u00e9velou","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vedang","family":"Murthy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Zilli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Nicosia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alberto","family":"Bossi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonard P.","family":"Bokhorst","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric","family":"Barret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Idir","family":"Ouzaid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul L.","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Ferrario","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cyrus","family":"Chargari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefano","family":"Arcangeli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Magne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Sargos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2025.104623_bib1","doi-asserted-by":"crossref","first-page":"308","DOI":"10.1053\/j.seminoncol.2013.04.006","article-title":"Multimodality therapy for patients with high-risk prostate cancer: current status and future directions","volume":"40","author":"Zaorsky","year":"2013","journal-title":"Semin Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib2","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.1056\/NEJMoa0810095","article-title":"Duration of androgen suppression in the treatment of prostate cancer","volume":"360","author":"Bolla","year":"2009","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.critrevonc.2025.104623_bib3","doi-asserted-by":"crossref","first-page":"320","DOI":"10.1016\/S1470-2045(15)70045-8","article-title":"High-dose radiotherapy with short-term or long-term androgen deprivation in localised prostate cancer (DART01\/05 GICOR): a randomised, controlled, phase 3 trial","volume":"16","author":"Zapatero","year":"2015","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib4","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.eururo.2022.04.003","article-title":"High-dose radiotherapy or androgen deprivation therapy (HEAT) as treatment intensification for localized prostate cancer: an individual patient-data network meta-analysis from the MARCAP consortium","volume":"82","author":"Kishan","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib5","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/S0140-6736(21)02437-5","article-title":"Abiraterone acetate and prednisolone with or without enzalutamide for high-risk non-metastatic prostate cancer: a meta-analysis of primary results from two randomised controlled phase 3 trials of the STAMPEDE platform protocol","volume":"399","author":"Attard","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2025.104623_bib6","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.radonc.2013.09.026","article-title":"Long-term results of the Dutch randomized prostate cancer trial: impact of dose-escalation on local, biochemical, clinical failure, and survival","volume":"110","author":"Heemsbergen","year":"2014","journal-title":"Radio. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib7","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1016\/j.ijrobp.2010.03.049","article-title":"70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial","volume":"80","author":"Beckendorf","year":"2011","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib8","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2018.0039","article-title":"Effect of standard vs dose-escalated radiation therapy for patients with intermediate-risk prostate cancer: the NRG oncology RTOG 0126 randomized clinical trial","volume":"4","author":"Michalski","year":"2018","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib9","doi-asserted-by":"crossref","first-page":"LBA259","DOI":"10.1200\/JCO.2024.42.4_suppl.LBA259","article-title":"Long-term results of dose escalation (80 vs 70 Gy) combined with long-term androgen deprivation in high-risk prostate cancers: GETUG-AFU 18 randomized trial","volume":"42","author":"Hennequin","year":"2024","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104623_bib10","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.18.01097","article-title":"Hypofractionated radiation therapy for localized prostate cancer: an ASTRO, ASCO, and AUA evidence-based guideline","volume":"36","author":"Morgan","year":"2018","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib11","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.3389\/fonc.2019.01378","article-title":"A brief review of low-dose rate (LDR) and high-dose rate (HDR) brachytherapy boost for high-risk prostate","volume":"9","author":"Fischer-Valuck","year":"2019","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib12","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1200\/JCO.20.02873","article-title":"Focal boost to the intraprostatic tumor in external beam radiotherapy for patients with localized prostate cancer: results from the FLAME randomized phase III trial","volume":"39","author":"Kerkmeijer","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.critrevonc.2025.104623_bib13","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1016\/j.ijrobp.2023.09.032","article-title":"Interim toxicity analysis from the randomized HERMES trial of 2- and 5-fraction magnetic resonance imaging-guided adaptive prostate radiation therapy","volume":"118","author":"Westley","year":"2024","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib14","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.1200\/JCO.20.03282","article-title":"Prostate-only versus whole-pelvic radiation therapy in high-risk and very high-risk prostate cancer (POP-RT): outcomes from phase iii randomized controlled trial","volume":"39","author":"Murthy","year":"2021","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib15","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1016\/j.juro.2015.06.100","article-title":"Anatomical patterns of recurrence following biochemical relapse in the dose escalation era of external beam radiotherapy for prostate cancer","volume":"194","author":"Zumsteg","year":"2015","journal-title":"J. Urol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib16","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1016\/j.eururo.2022.07.011","article-title":"Local failure events in prostate cancer treated with radiotherapy: a pooled analysis of 18 randomized trials from the meta-analysis of randomized trials in cancer of the prostate consortium (LEVIATHAN)","volume":"82","author":"Ma","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib17","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.eururo.2019.10.008","article-title":"Local failure and survival after definitive radiotherapy for aggressive prostate cancer: an individual patient-level meta-analysis of six randomized trials","volume":"77","author":"Kishan","year":"2020","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib18","doi-asserted-by":"crossref","first-page":"108","DOI":"10.1016\/j.ijrobp.2019.09.007","article-title":"Hyprofractionated versus conventionally fractionated radiation therapy for patients with intermediate- or high-risk, localized, prostate cancer: 7-year outcomes from the randomized, multicenter, open-label, phase 3 HYPRO trial","volume":"106","author":"de Vries","year":"2020","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib19","doi-asserted-by":"crossref","DOI":"10.1016\/j.euo.2024.01.008","article-title":"Prostate virtual high-dose-rate brachytherapy boost: 5-year results from the prometheus prospective multicentre trial","author":"Wegener","year":"2024","journal-title":"Eur. Urol. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib20","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1016\/j.ijrobp.2016.11.026","volume":"98","author":"Morris","year":"2017","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib21","doi-asserted-by":"crossref","DOI":"10.1016\/j.radonc.2024.110568","article-title":"Stereotactic body radiotherapy with a focal boost to the intraprostatic tumor for intermediate and high risk prostate cancer: 5-year efficacy and toxicity in the hypo-FLAME trial","volume":"201","author":"Draulans","year":"2024","journal-title":"Radio. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib22","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2022.6558","article-title":"Magnetic resonance imaging-guided vs computed tomography-guided stereotactic body radiotherapy for prostate cancer: the MIRAGE randomized clinical trial","author":"Kishan","year":"2023","journal-title":"JAMA Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib23","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1016\/j.ijrobp.2016.06.2455","article-title":"Is there a role for pelvic irradiation in localized prostate adenocarcinoma? update of the long-term survival results of the GETUG-01 randomized study","volume":"96","author":"Pommier","year":"2016","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib24","doi-asserted-by":"crossref","first-page":"1504","DOI":"10.1016\/S1470-2045(18)30528-X","article-title":"Sequence of hormonal therapy and radiotherapy field size in unfavourable, localised prostate cancer (NRG\/RTOG 9413): long-term results of a randomised, phase 3 trial","volume":"19","author":"Roach","year":"2018","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib25","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ctrv.2015.10.005","article-title":"Definition of lymph node areas for radiotherapy of prostate cancer: a critical literature review by the French genito-urinary group and the french association of urology (GETUG-AFU)","volume":"41","author":"Sargos","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.critrevonc.2025.104623_bib26","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1016\/j.clon.2024.04.001","article-title":"Patterns of failure after prostate-only radiotherapy in high-risk prostate cancer: implications for refining pelvic nodal contouring guidelines","volume":"36","author":"Singh","year":"2024","journal-title":"Clin. Oncol. (R. Coll. Radio. )"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104623_bib27","article-title":"Late urinary toxicity and QOL with pelvic radiotherapy for high-risk prostate cancer: Dose-effect relations in the POP-RT randomized phase III trial","volume":"S0360-3016","author":"Maitre","year":"2024","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib28","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.ijrobp.2022.07.2323","article-title":"Conventional vs. hypofractionated, radiotherapy for high-risk prostate cancer: 7-year outcomes of the randomized, non-inferiority, phase 3 PCS5 trial","volume":"114","author":"Niazi","year":"2022","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib29","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1186\/s12885-015-1886-5","article-title":"Helical intensity-modulated radiotherapy of the pelvic lymph nodes with a simultaneous integrated boost to the prostate - first results of the PLATIN 1 trial","volume":"15","author":"Habl","year":"2015","journal-title":"BMC Cancer"},{"key":"10.1016\/j.critrevonc.2025.104623_bib30","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s12253-019-00623-2","article-title":"Acute and late toxicity after moderate hypofractionation with simultaneous integrated boost (SIB) radiation therapy for prostate cancer. a single institution, prospective study","volume":"26","author":"Jorgo","year":"2020","journal-title":"Pathol. Oncol. Res"},{"key":"10.1016\/j.critrevonc.2025.104623_bib31","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/j.ijrobp.2010.11.003","article-title":"Hypofractionated concomitant intensity-modulated radiotherapy boost for high-risk prostate cancer: late toxicity","volume":"82","author":"Quon","year":"2012","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib32","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.radonc.2021.07.018","article-title":"Elective pelvic nodal irradiation with a simultaneous hypofractionated integrated prostate boost for localized high risk prostate cancer: long term results from a prospective clinical trial","volume":"163","author":"Glicksman","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib33","doi-asserted-by":"crossref","first-page":"4970","DOI":"10.3390\/cancers13194970","article-title":"Ten year results of extensive nodal radiotherapy and moderately hypofractionated simultaneous integrated boost in unfavorable intermediate-, high-, and very high-risk prostate cancer","volume":"13","author":"Di Muzio","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104623_bib34","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1097\/COC.0000000000000133","article-title":"Late toxicity and outcomes in high-risk prostate cancer patients treated with hypofractionated IMRT and long-term androgen suppression treatment","volume":"40","author":"Pervez","year":"2017","journal-title":"Am. J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib35","doi-asserted-by":"crossref","first-page":"751","DOI":"10.3389\/fonc.2019.00751","article-title":"Elective node irradiation with integrated boost to the prostate using helical IMRT\u2013clinical outcome of the prospective PLATIN-1 trial","volume":"9","author":"Koerber","year":"2019","journal-title":"Front Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib36","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.prro.2021.03.006","article-title":"Long-term outcomes of dose-escalated pelvic lymph node intensity-modulated radiation therapy (IMRT) with a simultaneous hypofractionated boost to the prostate for very high-risk adenocarcinoma of the prostate: a prospective phase II clinical trial","volume":"11","author":"Hall","year":"2021","journal-title":"Pract. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib37","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1186\/1748-717X-9-214","article-title":"Image guided intensity modulated hypofractionated radiotherapy in high-risk prostate cancer patients treated four or five times per week: analysis of toxicity and preliminary results","volume":"9","author":"Valeriani","year":"2014","journal-title":"Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib38","doi-asserted-by":"crossref","first-page":"e514","DOI":"10.1016\/j.prro.2020.06.012","article-title":"Long-term results of moderate hypofractionation to prostate and pelvic nodes plus androgen suppression in high-risk prostate cancer","volume":"10","author":"Faria","year":"2020","journal-title":"Pract. Radiat. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104623_bib39","first-page":"08131","article-title":"Randomized trial of concomitant hypofractionated intensity modulated radiation therapy boost versus conventionally fractionated intensity modulated radiation therapy boost for localized high-risk prostate cancer (pHART2-RCT)","volume":"S0360-3016","author":"Glicksman","year":"2023","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib40","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1016\/j.ijrobp.2021.01.016","article-title":"Stereotactic body radiotherapy for high-risk localized carcinoma of the prostate (SHARP) consortium: analysis of 344 prospectively treated patients","volume":"110","author":"van Dams","year":"2021","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib41","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.1016\/j.ijrobp.2010.10.075","article-title":"Dose-fractionation sensitivity of prostate cancer deduced from radiotherapy outcomes of 5,969 patients in seven international institutional datasets: \u03b1\/\u03b2 =\u20091.4 (0.9\u20132.2) Gy","volume":"82","author":"Miralbell","year":"2012","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib42","doi-asserted-by":"crossref","first-page":"1438","DOI":"10.1016\/j.ijrobp.2018.07.2005","article-title":"Phase 1-2 study of stereotactic ablative radiotherapy including regional lymph node irradiation in patients with high-risk prostate cancer (SATURN): early toxicity and quality of life","volume":"102","author":"Musunuru","year":"2018","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib43","doi-asserted-by":"crossref","DOI":"10.1016\/j.clon.2019.09.046","article-title":"A phase I\/II study of stereotactic hypofractionated once-weekly radiation therapy (SHORT) for prostate cancer","volume":"32","author":"Mallick","year":"2020","journal-title":"Clin. Oncol. (R. Coll. Radio. )"},{"key":"10.1016\/j.critrevonc.2025.104623_bib44","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1016\/j.clon.2018.03.004","article-title":"Early results of extreme hypofractionation using stereotactic body radiation therapy for high-risk, very high-risk and node-positive prostate cancer","volume":"30","author":"Murthy","year":"2018","journal-title":"Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib45","doi-asserted-by":"crossref","first-page":"e48","DOI":"10.1016\/j.prro.2023.08.006","article-title":"Long-term outcomes following fairly brief androgen suppression and stereotactic radiation therapy in high-risk prostate cancer: update from the FASTR\/FASTR-2 trials","volume":"14","author":"Tang","year":"2024","journal-title":"Pr. Radiat. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib46","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1016\/j.ijrobp.2020.11.008","article-title":"Long-term results of NRG oncology\/RTOG 0321: a phase II trial of combined high dose rate brachytherapy and external beam radiation therapy for adenocarcinoma of the prostate","volume":"110","author":"Hsu","year":"2021","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib47","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.radonc.2012.07.003","article-title":"Long term results of a prospective dose escalation phase-II trial: Interstitial pulsed-dose-rate brachytherapy as boost for intermediate- and high-risk prostate cancer","volume":"104","author":"Lettmaier","year":"2012","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib48","article-title":"External-beam radiation therapy and high\u2013dose rate brachytherapy combined with long-term androgen deprivation therapy in high and very high prostate cancer: preliminary data on clinical outcome","volume":"82","author":"Mart\u00ednez-Monge","year":"2012","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib49","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.brachy.2015.12.008","article-title":"Dose escalation with external beam radiation therapy and high-dose-rate brachytherapy combined with long-term androgen deprivation therapy in high and very high risk prostate cancer: comparison of two consecutive high-dose-rate schemes","volume":"15","author":"Olarte","year":"2016","journal-title":"Brachytherapy"},{"key":"10.1016\/j.critrevonc.2025.104623_bib50","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1016\/j.ijrobp.2022.09.058","article-title":"Standard and hypofractionated dose escalation to intraprostatic tumor nodules in localized prostate cancer: 5-year efficacy and toxicity in the DELINEATE trial","volume":"115","author":"Tree","year":"2023","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib51","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.radonc.2020.03.015","article-title":"Primary endpoint analysis of the multicentre phase II hypo-FLAME trial for intermediate and high risk prostate cancer","volume":"147","author":"Draulans","year":"2020","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib52","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.radonc.2021.05.024","article-title":"Stereotactic pelvic radiotherapy with HDR boost for dose escalation in intermediate and high-risk prostate cancer (SPARE): efficacy, toxicity and quality of life","volume":"161","author":"Musunuru","year":"2021","journal-title":"Radiother. Oncol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijrobp.2023.02.054","article-title":"A randomized feasibility trial of stereotactic prostate radiation therapy with or without elective nodal irradiation in high-risk localized prostate cancer (SPORT Trial)","author":"Houlihan","year":"2023","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib54","doi-asserted-by":"crossref","first-page":"3484","DOI":"10.3390\/cancers14143484","article-title":"A prospective study of stereotactic body radiotherapy (SBRT) with concomitant whole-pelvic radiotherapy (wprt) for high-risk localized prostate cancer patients using 1.5 tesla magnetic resonance guidance: the preliminary clinical outcome","volume":"14","author":"Poon","year":"2022","journal-title":"Cancers"},{"key":"10.1016\/j.critrevonc.2025.104623_bib55","doi-asserted-by":"crossref","first-page":"e105","DOI":"10.1016\/j.eururo.2022.06.024","article-title":"Re: Pawel Rajwa, Benjamin Pradere, Giorgio Gandaglia, et al. Intensification of systemic therapy in addition to definitive local treatment in nonmetastatic unfavourable prostate cancer: a systematic review and meta-analysis. Eur Urol 2022;82:82-96","volume":"82","author":"Murthy","year":"2022","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib56","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.ijrobp.2020.08.034","article-title":"NRG oncology updated international consensus atlas on pelvic lymph node volumes for intact and postoperative prostate cancer","volume":"109","author":"Hall","year":"2021","journal-title":"Int. J. Radiat. Oncol. *Biol. *Phys."},{"issue":"23","key":"10.1016\/j.critrevonc.2025.104623_bib57","first-page":"07680","article-title":"Consensus delineation guidelines for pelvic lymph node radiotherapy of prostate cancer: on behalf of the francophone group of urological radiation therapy (GFRU)","volume":"S0360-3016","author":"Hertogh","year":"2023","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib58","doi-asserted-by":"crossref","DOI":"10.1016\/j.euf.2024.01.008","article-title":"Cardiovascular mortality and duration of androgen deprivation in locally advanced prostate cancer: long-term update of NRG\/RTOG 9202","author":"Mak","year":"2024","journal-title":"Eur. Urol. Focus"},{"key":"10.1016\/j.critrevonc.2025.104623_bib59","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0269192","article-title":"Cost-utility analysis of adding abiraterone acetate plus prednisone\/prednisolone to long-term hormone therapy in newly diagnosed advanced prostate cancer in England: Lifetime decision model based on STAMPEDE trial data","volume":"17","author":"Clarke","year":"2022","journal-title":"PLoS One"},{"issue":"24","key":"10.1016\/j.critrevonc.2025.104623_bib60","article-title":"Magnetic resonance imaging versus computed tomography guidance for stereotactic body radiotherapy in prostate cancer: 2-year outcomes from the MIRAGE randomized clinical trial","volume":"S0302-2838","author":"Kishan","year":"2024","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib61","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1016\/j.eururo.2020.07.029","article-title":"When what you see is not always what you get: raising the bar of evidence for new diagnostic imaging modalities","volume":"79","author":"Sundahl","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib62","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1016\/j.ijrobp.2022.12.035","article-title":"Analysis of a biopsy-based genomic classifier in high-risk prostate cancer: meta-analysis of the NRG oncology\/radiation therapy oncology group 9202, 9413, and 9902 phase 3 randomized trials","volume":"116","author":"Nguyen","year":"2023","journal-title":"Int J. Radiat. Oncol. Biol. Phys."},{"key":"10.1016\/j.critrevonc.2025.104623_bib63","doi-asserted-by":"crossref","DOI":"10.1056\/EVIDoa2300023","article-title":"Artificial intelligence predictive model for hormone therapy use in prostate cancer","volume":"2","author":"Spratt","year":"2023","journal-title":"NEJM Evid."},{"key":"10.1016\/j.critrevonc.2025.104623_bib64","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/j.eururo.2020.09.042","article-title":"EAU-EANM-ESTRO-ESUR-SIOG guidelines on prostate cancer\u20142020 update. part 1: screening, diagnosis, and local treatment with curative intent","volume":"79","author":"Mottet","year":"2021","journal-title":"Eur. Urol."},{"key":"10.1016\/j.critrevonc.2025.104623_bib65","doi-asserted-by":"crossref","first-page":"3287","DOI":"10.1007\/s00345-023-04579-6","article-title":"State of the art and future challenges of urethra-sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature","volume":"41","author":"Le Guevelou","year":"2023","journal-title":"World J. Urol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000113?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842825000113?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,21]],"date-time":"2025-02-21T08:23:45Z","timestamp":1740126225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842825000113"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3]]},"references-count":65,"alternative-id":["S1040842825000113"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104623","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2025,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"\u00ab Augmented radiotherapy \u00bb in the management of high-risk prostate cancer (PCa): A systematic review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2025.104623","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104623"}}